Zhang Y#, Wang S#, Wu Y#, Hou W#, Yuan L#, Shen C#, Wang J, Ye J, Zheng Q, Ma J, Xu J, Wei M, Li Z, Nian S, Xiong H, Zhang L, Shi Y, Fu B, Cao J, Yang C, Li Z, Yang T, Liu L, Yu H, Hu J, Ge S, Chen Y, Zhang T, Zhang J, Cheng T*, Yuan Q*, Xia N*. Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods. 2021 Feb 15;5(2):2001031. (IF:12.130)
Wang SJ, Chen ZM, Wei M, Liu JQ, Li ZL, Shi TS, Nian S, Fu R, Wu YT, Zhang YL, Wang YB, Zhang TY, Zhang J, Xiong JH, Tong SP, Ge SX, Yuan Q, Xia NS. Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection. Emerg Microbes Infect. 2021 Dec;10(1):37-50. (IF: 5.776)
Le Chang#, Wangheng Hou#, Lei Zhao#, Yali Zhang#, Yanbin Wang, Linfeng Wu, TingtingXu, Lilin Wang, Juan Wang, Jian Ma, Lan Wang, Junpeng Zhao, Jing Xu, Juan Dong, YingYan, Ru Yang, Yu Li, Fei Guo, Wenjuan Cheng, Yingying Su, Jinfeng Zeng, Wei Han, Tong Cheng, Jun Zhang, Quan Yuan*, Ningshao Xia, Lunan Wang*. Nature Communications, 2021, Accepted. (IF: 12.121)
Zhao, J. #, Yuan, Q. #, Wang, H. #, Liu, W. #, Liao, X. #, Su, Y. #, Wang, X., Yuan, J., Li, T., Li, J., Qian, S., Hong, C., Wang, F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., … Zhang, Z. (2020). Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 71(16), 2027–2034. (IF:8.313)
Lu J#, Lu G#, Tan S#, Xia J#, Xiong H#, Yu X, Qi Q, Yu X, Li L, Yu H, Xia N, Zhang T*, Xu Y*, Lin J*. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Research. 2020 Oct;30(10):936-939.(IF:20.507)
Zhang TY#, Guo XR#, Wu YT#, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Chen PJ, Zhang J*, Yuan Q* and Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2020 Feb;69(2):343-354. (IF:19.819)
Zhang TY#, Chen HY#, Cao JL#, Xiong HL, Li TL, Kang XZ, Zhao JH, Yin B, Yuan Q*, Xue D*, Xia NS*, Yuan YA. Structural and functional analyses of the Hepatitis B virus X protein BH3-like domain and its interaction with Bcl-xL. Nature Communications. 2019, 10: 3192. (IF: 12.121)
Zhang TY†, Guo XR†, Wu YT†, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Chen PJ, Zhang J*, Yuan Q* and Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2019. (IF: 19.819)
Yuan L†, Zhang Y†, Liu X†, Chen Y, Zhang L, Cao J, Li X, Wang M, Wu K, Zhang J, Liu G, Tang Q, Yuan Q*, Cheng T*, Xia N*. Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice. Theranostics. 2019; 9(7):2115-2128. (IF: 8.579)
Zhang YL†, Gao Y†, Cao JL, Zhao JH, Zhang TY, Yang CL, Xiong HL, Wang YB, Ou SH*, Cheng T, Chen CR*, Yuan Q*, Xia NS. Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. Emerg Microbes Infect. 2019;8(1):724-733. (IF: 5.776)
Liu X†, Yuan L†, Zhang L, Mu Y, Li X, Liu C, Lv P, Zhang Y, Cheng T, Yuan Q*, Xia N, Chen X, Liu G*. Bioinspired Artificial Nanodecoys for Hepatitis B Virus. Angewandte chemie-international edition. 2018; 57(38):12499-12503. (IF: 12.959)
Zhang JF†, Xiong HL†, Cao JL, Wang SJ, Guo XR, Lin BY, Zhang Y, Zhao JH, Wang YB, Zhang TY*, Yuan Q*, Zhang J, Xia NS. A cell-penetrating whole molecule antibody targeting intracellular HBx suppress hepatitis B virus via TRIM21-dependent pathway, Theranostics.2018, 8(2): 549-562. (IF: 8.579)
Zhang TY†, Yuan Q†*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo WX, Cheng T, Chen YX, Tao MH, Shih JW, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*, Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut, 2016, 65(4): 658-71. (IF: 19.819)
Fan F†, He Z†, Kong LL†, Chen Q†, Yuan Q†, Zhang S, Ye J, Liu H, Sun X, Geng J, Yuan L, Hong L, Xiao C, Zhang W, Sun X, Li Y, Wang P, Huang L, Wu X, Ji Z, Wu Q, Xia NS, Gray NS, Chen L, Yun CH*, Deng X*, Zhou D*. Pharmacological targeting of kinases mst1 and mst2 augments tissue repair and regeneration. Science Translational Medicine, 2016; 8(352), 352ra108. (IF: 16.304)
Fan R†, Sun J†, Yuan Q†, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N*, Hou J*. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016, 65(2):313-20. (IF: 19.819)